Recent Posts
- Zemcelpro® (dorocubicel) positive results in high- and very high-risk blood cancers to be reported at the EBMT 2026 Annual Meeting
- Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
- Zemcelpro® (UM171 Cell Therapy) improved outcomes compared with common graft sources: European real-world evidence
- Zemcelpro® (UM171 Cell Therapy) receives EC authorization as the first and only cell therapy for blood cancer patients without access to suitable donor cells
- Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells
Recent Comments
No comments to show.